公开(公告)号：US10414809B2

公开(公告)日：2019-09-17

申请号：US15507650

申请日：2015-09-01

Applicant: ACADEMIA SINICA

Inventor： Che-Kun James Shen ,  Yu-Chiau Shyu

IPC: C07K14/47 ,  A01K67/027 ,  A61K38/17 ,  A61K45/06

Abstract: The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.

公开(公告)号：US10398786B2

公开(公告)日：2019-09-03

申请号：US15567931

申请日：2016-04-19

Applicant: Academia Sinica

Inventor： Patrick C. H. Hsieh ,  Yuan-Yuan Cheng

IPC: A61P9/10 ,  A61K38/17 ,  A61K45/06 ,  A61K48/00 ,  A61K31/713

Abstract: A combination of active agents selected from a FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor and the uses thereof in promoting cardiomyocyte proliferation and treating heart diseases in a subject in need of the treatment.

公开(公告)号：US20190247371A1

公开(公告)日：2019-08-15

申请号：US16335765

申请日：2017-09-21

Applicant: Tsann-Long SU ,  ACADEMIA SINICA

Inventor： Tsann-Long SU ,  Te-Chang LEE

IPC: A61K31/437 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/437 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/24 ,  A61K45/06 ,  A61P35/00 ,  A61K2300/00

Abstract: A method for treating small cell lung cancer (SCLC). In the method, a therapeutically effective amount of a compound of Formula I: wherein R1, R2 and R3 have the definitions disclosed in the specification is administered alone or in combination with one or more anticancer agents, or surgery, radiation therapy, chemotherapy, and/or targeted therapy.

公开(公告)号：US20190225579A1

公开(公告)日：2019-07-25

申请号：US16313057

申请日：2017-06-14

Applicant: Academia Sinica

Inventor： Wei-Chieh CHENG

IPC: C07D207/02 ,  A61P3/00 ,  A61K31/7028 ,  A61K38/47

Abstract: Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with —COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).

公开(公告)号：US10342858B2

公开(公告)日：2019-07-09

申请号：US14832993

申请日：2015-08-21

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu

IPC: C07H5/02 ,  C07H5/04 ,  C07H5/06 ,  A61K39/00 ,  C07H15/04 ,  C07H15/26 ,  C07K16/30 ,  C07K16/44 ,  C08B37/00 ,  A61K31/715 ,  A61K31/7028

Abstract: The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.

公开(公告)号：US10338069B2

公开(公告)日：2019-07-02

申请号：US14376837

申请日：2011-04-12

Applicant: Chi-Huey Wong ,  Chung-Yi Wu ,  Chi-Hui Liang ,  An-Suei Yang

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Chi-Hui Liang ,  An-Suei Yang

IPC: G01N33/569 ,  G01N33/53 ,  G01N33/543

Abstract: Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed. Sandwich assays using gold nanoparticles conjugated to phage particles comprising influenza virus-specific antibodies for detecting multiple serotypes using a single reaction are provided. Plurality of glycans directed to specific target HA of influenza virus comprises the array. Detector molecules comprising noble metals conjugated to (a) phage display particles expressing antibodies against hemagglutinin and (b) neuraminidase binding agents are disclosed.

公开(公告)号：US10322165B2

公开(公告)日：2019-06-18

申请号：US15660116

申请日：2017-07-26

Applicant: ACADEMIA SINICA

Inventor： Ming-Daw Tsai ,  Tong-You Wade Wei ,  Pei-Yu Wu

IPC: A61K38/00 ,  A61K38/17 ,  C07K14/47 ,  A61K45/06 ,  C12N15/113

Abstract: The present invention relates to use of TRAF-interacting protein with an FHA domain (TIFA) antagonists for treating diseases. Particularly, the present invention relates to an isolated peptide fragment from TIFA which acts as a dominant negative inhibitor of TIFA and is effective in treating cancer or an inflammatory disorder. The present invention also relates to a method for predicting cancer prognosis based on the TIFA expression level in a subject in need. The present invention further relates to a method for treating a disease via TIFA silencing.

公开(公告)号：US20190170745A1

公开(公告)日：2019-06-06

申请号：US16322014

申请日：2017-07-28

Applicant: Che-Ming Jack HU ,  ACADEMIA SINICA

Inventor： Che-Ming Jack HU ,  Hui-Wen CHEN ,  Yuan-I CHEN ,  Chen-Ying CHEIN ,  Jung-Chen LIN

IPC: G01N33/556 ,  G01N33/543 ,  C12N5/078

Abstract: A method of generating an internally fixed lipid vesicle, comprising: providing a precursor lipid vesicle that contains an aqueous interior enclosed by a lipid membrane, wherein the lipid membrane of the precursor lipid vesicle is non-permeable to a crosslinker; permeabilizing the lipid membrane transiently to generate a permeable vesicle; contacting the permeable vesicle with an inactive activatable crosslinker, whereby the inactive activatable crosslinker enters the permeable vesicle; allowing the permeable vesicle to return to a non-permeable vesicle; removing any extravesicular crosslinker; and activating the inactive activatable crosslinker to allow crosslinking to occur inside the non-permeable vesicle, whereby an internally fixed lipid vesicle is generated.

公开(公告)号：US10307470B2

公开(公告)日：2019-06-04

申请号：US14906663

申请日：2014-07-26

Applicant: ACADEMIA SINICA ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Hsien-Yeh Hsu ,  Shih-Fen Liao ,  Chi-Hui Liang

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Hsien-Yeh Hsu ,  Shih-Fen Liao ,  Chi-Hui Liang

IPC: A61K39/00 ,  A61K36/074

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer comprising FMS, the fucose-enriched polysaccharide fraction from Reishi F3, are provided. Compositions comprise fucose-enriched Reishi polysaccharide fraction (FMS) MW=˜35 kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-α-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain Immunogenic compositions comprising glycolipid adjuvants are provided. Antibodies generated by immunogenic compositions disclosed herein bind cancer cells comprising antigens Globo H, Globo H, Gb3, Gb4, Gb5 (SSEA-3) and SSEA-4 on the cell surface.

公开(公告)号：US10273411B2

公开(公告)日：2019-04-30

申请号：US15309707

申请日：2015-05-07

Applicant: Academia Sinica ,  Frank H. Shu

Inventor： Frank H. Shu ,  Fen-Tair Luo ,  Michael J. Cai

IPC: C10B49/14 ,  C10B39/06 ,  C10L9/08 ,  C10B57/18 ,  C10L5/44 ,  C10B53/02 ,  C10B53/08

Abstract: A compact, transportable batch-process supertorrefaction system includes at least one supertorrefying unit, a liquid tank containing molten salt, and a wash tank including a plurality of basins containing water having different temperatures and different salinity. The liquid tank and the wash tank sequentially supply the molten salt and the water to a receiving space of the at least one supertorrefying unit to supertorrefy the biomass into charcoal and to rinse and cool the charcoal, respectively. The plurality of basins of the wash tank sequentially supply water having different temperatures and salinity to the same receiving space to gradually rinse and cool the charcoal. The biomass is not moved in the at least one supertorrfeying unit during biomass supertorrefaction. The charcoal is not moved during charcoal cooling.